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Abstract
The incidence of adrenal involvement in MEN1 syndrome has been reported between 9 and 45%, while the incidence
of adrenocortical carcinoma (ACC) in MEN1 patients has been reported between 2.6 and 6%. In the literature data only
unilateral development of ACCs in MEN1 patients has been reported. We report a 31 years-old female MEN1-patient, in
whom hyperplasia of the parathyroid glands, prolactinoma, non functioning pancreatic endocrine carcinoma and
functioning bilateral adrenal carcinomas were diagnosed. Interestingly, a not previously described in the literature data,
novel germline mutation (p.E45V) in exon 2 of MEN1 gene, was detected. The association of exon 2 mutation of the
MEN1 gene with bilateral adrenal carcinomas in MEN1 syndrome, should be further investigated.
Introduction
Multiple endocrine neoplasia type 1 (MEN1) is an auto-
somal dominant disorder with penetrance reaching
100% with age [1].
It is characterized by parathyroid glands hyperplasia,
anterior pituitary gland tumours and pancreatic islets
tumours [2]. However, other endocrine and non-endocrine
lesions, such as carcinoids of the bronchi [3], gastrointest-
inal tract [4] and thymus [5], lipomas, angiofibromas and
collagenomas [6,7] can also occur with low frequency,
while combinations of more than twenty different endo-
crine and non-endocrine tumours and lesions have been
reported [8-12].
A simple definition of MEN 1 can not cover all index
cases and all families. As a practical definition, sporadic
MEN1 is characterised by the occurrence of primary
tumours involving two of the three main MEN1 related
endocrine tissues within a single patient, while familial
MEN1 is defined as at least one MEN1 case plus at least
one first degree relative with one of those three tumors [13].
The incidence of adrenal lesions in MEN1 patients
varies between 9 and 45% [14-20] and they usually
develop in patients with mutations in exons 2 and 10
[18]. Other authors stated that they are mainly unilateral
(55-79%) [18,20-22], others addressed them as mainly
bilateral (60%) [15], but all agree that the majority of
these lesions are hyperplastic and nonfunctioning, caus-
ing minimal morbidity. Functioning tumors like pheo-
chromocytoma or tumors causing hypercortisolemia and
hyperaldosteronism are rare manifestations of MEN1
[23]. The incidence of adreonocortical carcinoma (ACC)
in MEN1 patients has been reported between 2.6 [20]
and 6% [17,18,22]. Although involvement of the adrenal
gland has been reported in approximately 40% of MEN1
patients and has been found to represent bilateral hyper-
plasia, adenoma and in a few cases carcinoma, bilateral
adrenal carcinoma has not been previously reported.
Herewith, we report a 31 years-old female patient with
sporadic form of MEN1 in whom functioning bilateral
adrenocortical carcinomas were diagnosed. Interestingly
enough, a novel germline mutation in exon 2 of MEN1
gene, was detected.
Case Report
A 31 years-old female patient with the preoperative
diagnosis of MEN1, was referred by the Endocrinologists
to the 1st Department of Surgery, for further evaluation
and treatment.
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On clinical examination, centripetal obesity, moon
face, fat deposition over the thoracocervical spine (buf-
falo hump), excessive terminal hair in various parts of
her body and four angiofibromas in her face, were
observed. Her arterial blood pressure was moderately
abnormal (155/80 mmHg), while she reported menstrual
irregularity (infrequent uterine bleeding) and easy bruis-
ing. She was suffering from diabetes mellitus since 2002
and she was currently on glargine insulin, whereas she
reported having been prescribed Dopamine agonists for
her pituitary prolactinoma lesion. Her family history was
insignificant
The preoperative imaging investigation of the patient
included: magnetic resonance imaging (MRI) of the
head disclosing a 1.4 × 1.3 cm pituitary adenoma,
cervical ultrasound and Tc99 m Sestamibi-scans both
disclosing hyperplasia of the parathyroid glands, abdom-
inal MRI scan and endoscopic ultrasound (EUS) both
disclosing a 4.5 × 3.0 cm tumor in the body and tail of
the pancreas, fine needle aspiration biopsy (FNAB) of
the pancreatic tumor under EUS guidance concluding in
histological findings compatible to neuroendocrine
tumor, somatostatin receptor imaging with Indium 111
(OctreoScan®) disclosing radionuclide material uptake
in the left upper quadrant of the abdominal cavity at
some point between the left lobe of the liver and the
spleen, while in the abdominal MRI scan bilateral adre-
nal tumors (right adrenal 8.0 Χ 4.5 cm and left adrenal
7.5 × 5.5 cm) (Figure 1), as well as a fully calcified ecto-
pic left kidney into the pelvis, were detected. Finally, a
Figure 1 MRI scan of the upper abdomen disclosing bilateral adrenal tumors.
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DMSA renal scan disclosed only 17% renal function of
the ectopic left kidney.
The preoperative hormonal evaluation of the patient is
presented in Table 1. She was further submitted to an
Overnight Dexamethasone Suppression Test (ODST),
which failed to suppress the morning cortisol levels-
which were 627 nM/L (< 50 nM/L), whereas the Urinary
Free Cortisol levels were elevated- 473 μg/24h (55-286),
signifying hyper-cortisolism. The ODST, in concordance
with the ACTH level, unmasked a Cushing syndrome
caused due to adrenal production of cortisol. Moreover,
the possibility of adrenocortical carcinoma was consid-
ered high in the light of the high levels of androgens. Due
to moderate high levels of arterial blood pressure (155/80
mmHg), she had her 24 hours urine output collected.
800mL of urine were collected and the laboratory results
were as follows: Adrenaline 3 μg/24h (1.7-22.4), Noradre-
naline 29 μg/24h (12-85), Metanefrine 337 μg/24h (100-
800), Normetanefrine 298 μg/24h (88-444), VMA 4 μg/
24h (1.8-6.7) and Dopamine 47 μg/24h (65-400).
After the completion of the imaging investigation and
the laboratory evaluation, the diagnosis of sporadic form
of MEN1 syndrome consisting of: (i) a 1.4 × 1.3 cm pro-
lactine producing pituitary adenoma, (ii) primary hyper-
parathyroidism due to hyperplasia of the parathyroid
glands, (iii) a 4.5 × 3.0 cm non functioning endocrine
tumor in the body and tail of the pancreas and
(iv) functioning bilateral adrenal tumors, was established.
The patient was submitted to an exploratory laparot-
omy through a bilateral subcostal incision. She under-
went distal pancreatectomy, splenectomy, bilateral
adrenalectomy and nephrectomy of the ectopic left
kidney. Parathyroidectomy was postponed until the
development of clinical or laboratory findings compatible
to hyperparathyroidism. The patient had an uneventful
postoperative recovery and she was discharge on the
7th postoperative day.
The histological findings were as follows: Distal pan-
creas (size 9.5 × 5.1 × 2.8 cm). Grossly, the pancreatic
tissue exhibited multiple cystic and hemorrhagic lesions
ranging from 0.3 to 2 cm in maximum diameter. In the
peripancreatic fat five lymphnodes measuring 0.4 to
0.6 cm, were detected. Microscopically, the pancreatic
lesions corresponded to neoplastic tissue consisting of
uniform neoplastic cells with scant eosinophilic cyto-
plasm and stippled nuclei, arranged in nests and trabe-
cula. There was mild to moderate nuclear atypia and
the mitotic figures were less than 2 per 10 HPF (magni-
fication X40). Neoplastic emboli in pancreatic vessels, as
well as tumor nests in the peripancreatic fat were also
evident. The tumor appeared to extend within less than
0.3 cm of the surgical margins. The resected lymph-
nodes were free of metastatic deposits. The neoplastic
cells exhibited immunopositivity for neuroendocrine
markers (chromogranin and synaptophysin), while the
proliferation index assessed by Ki-67 immunohistochem-
istry was about 5%. Taking into account the above histo-
logical observations (especially that the proliferation
index was about 5%) as well as the data from the litera-
ture, the diagnosis of well-differentiated endocrine carci-
noma of the pancreas was established.
Both adrenals glands. The left one weighed 250 gr, mea-
sured 10.1 × 7.3 × 4.5 cm and upon sectioning, a well cir-
cumscribed brownish tumor with central calcification
sizing 7.5 × 5.5 × 4.1 cm, was found. The right adrenal
gland weighed 120gr and measured 10.5 × 5.5 × 3.7 cm.
Gross examination revealed the presence of a tumor mea-
suring 8 × 4 × 3 cm, with features similar to those of the
left gland, but without central calcification. Histologically,
both adrenal tumors showed features of adrenocortical
neoplasms. The neoplastic population consisted of round
to oval cells, with scant eosinophilic cytoplasm and moder-
ate to marked nuclear pleomorphism, arranged in a loose
growth pattern (Figure 2). Abnormal caryokinesis and inva-
sion of venous and sinusoid vessels were also observed.
Necrotic areas were present only in the tumor of the left
adrenal gland. Immunohistochemically, the cells were Mel-
anA and synaptophysin immunopositive. No immunostain-
ing for cytoceratin, chromogranin, EMA and CEA was
observed. The remaining non-neoplastic adrenal tissue
showed nodular hyperplasia. Based on the above findings,
both tumors corresponded to adrenocortical neoplasms
with malignant potential, according to Weiss’s criteria.
Following these results, the patient as well as her
mother and her sister were submitted to genetic test for
Table 1 Preoperative and postoperative serum hormonal
evaluation of the patient




ACTH 1-50 pg/ml 0.23
Cortisol 260-720 nM 834
Prolactin 2.7-20 ng/ml 25.7
Calcium 8.6-10.2 mg/dl 9.8
PTH 8-76 pg/ml 107
GH 0-10 μIU/ml 12
IGF 114-492 ng/ml 847
FSH 1.8-9.4 mIU/ml 0.42
LH 0.8-10.4 mIU/ml 1.1
TSH 0.3-4 mU/l 1.65
Testosterone 0.1-0.8 ng/ml 2 0.1
Δ4
Androstendione
0.5-4.7 ng/ml 14.7 0.38
DHEAs 99-340 μg/dl 950 0.01
Phosphorus 2.7-4.5 mg/dl 2.7
CgA 19-98 ng/ml 187
CA-125 < 30 U/ml 227 40
Griniatsos et al. World Journal of Surgical Oncology 2011, 9:6
http://www.wjso.com/content/9/1/6
Page 3 of 7
MEN1. A germline p.E45V mutation in exon 2 of the
MEN1 gene was detected, while none of the rest mem-
bers of the family expressed any genetic abnormality.
Due to the bilateral adrenalectomy she was prescribed
on Hydrocortisone and Flurohydrocortisone repletion
therapy. Her postoperative hormonal evaluation, soon
after having been discharged, is presented in Table 1.
Discussion
In the present report we describe a young female MEN1-
patient, in whom apart from the prolactine producing
pituitary adenoma, the hyperplasia of the parathyroid
glands and the well-differentiated non functioning pan-
creatic endocrine carcinoma, functioning bilateral adreno-
cortical carcinomas were diagnosed. A not previously
described, novel germline mutation (p.E45V) in exon 2 of
MEN1 gene was detected in the postoperative genetic test
for MEN1.
MEN1 is a tumor suppressor gene located at chromo-
some 11q13 loci, encoding a 67 kD nuclear protein of
610 amino acids, called menin [24]. Various types of
mutations scattered throughout the 10 coding exons of
the MEN1 gene inactivate the MEN1 gene.
Knudson’s two-hit model for tumorigenesis [10]
addresses that the first hit can take place either in germ-
line or in somatic tissue and compromise a small num-
ber of bases. The mutations are distributed across the
MEN1 reading frame, resulting in a great deal of novel
mutations, approximately 50%, in the index cases.
Mostly, they result in premature truncation of DNA
sequence, inactivating menin protein. The second hit is
usually a large chromosomal deletion, which lives no
normal functional allele. The second hit is in somatic
tissue and in most cases occurs postnataly.
The first clinical manifestation of MEN1 is hyperpar-
athyroidism, mainly due to multiglandular hyperplasia,
which usually affects more than 95% of all MEN1
patients [25]. Although there is no doubt that total para-
thyroidectomy constitutes the treatment of choice for
symptomatic hypercalcaemic MEN1 patients [2], the
decision for the timing for the parathyroid surgery
should take under account the severity of the PHPT
symptoms, the circulating PTH and calcium levels, the
presence of MEN1-associated endocrinopathies, espe-
cially the Zollinger-Ellison syndrome (ZES) and the
patient’s age [26]. Since the patient we describe, was
Figure 2 Histological section (H&E counterstain) of the adrenocortical neoplasm in the left adrenal gland, depicting cells with
moderate to marked nuclear pleomorphism (magnification X200).
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asymptomatic, had no evidence of ZES, meeting only
one (the age) of the proposed by the NIH criteria for
the treatment of asymptomatic primary hyperparathyr-
oidism [27], the parathyroidectomy was postponed for
the future.
Pancreatic tumours occur in about 30-75% of MEN1
patients and are the second commonest clinical manifes-
tation of MEN1 [28]. One third of pancreatic tumours
are non functioning and clinically silent, but the major-
ity of them produce excessive amounts of hormones
such as gastrin, insulin, glucagon, somatostatin, neuro-
tensin or vasoactive intestinal polypeptide and are asso-
ciated with distinct clinical syndromes [2]. Pancreatic
tumours can be multiple and scattered throughout the
whole pancreas, ranging in size from micro-adenomas
(slightly larger than unaffected islets) to macro-
adenomas larger than 0.5 cm [26]. Endoscopic ultra-
sound (EUS) constitutes the most sensitive imaging
method for the detection of small pancreatic endocrine
tumours in asymptomatic MEN1 patients (sensitivity >
75%), while the combination of EUS with Octreoscan
scintigraphy, increases the pancreatic tumoural detection
rate to 90% [29]. As general recommendation, patients
with positive imaging studies and no evidence of unre-
sectable metastases, should undergo surgical exploration
with intraoperative ultrasound [10]. Surgery is always
indicated for hormonal producing tumours, while for
asymptomatic patients pancreatic surgery can be
decided when the size of the lesion approaches 2 cm
[26]. It is generally accepted that large tumours in the
pancreatic body or tail should be treated by distal pan-
createctomy and splenectomy [30]. The preoperative
laboratory and imaging with EUS and Octreoscan work
up of the patient we describe, disclosed a non hormonal
producing but greater than 2 cm pancreatic tail tumour
with no evidence of metastatic disease. Thus, the patient
underwent an exploratory laparotomy, the intraoperative
ultrasonography did not disclosed any other pancreatic
lesion and distal pancreatectomy and splenectomy were
performed.
The incidence of pituitary adenomas in MEN1
patients varies between 10 and 60% [13], while their
symptoms depend on the type and the amount of the
pituitary hormone secretion and/or the compression
effects due to the size of the tumour [26]. Pituitary
tumours can be successfully managed by drug therapy,
reserving surgery and/or radiotherapy for large tumours
or irresectable residual disease [2]. The lack of compres-
sion symptoms explains why the patient we describe,
was treated conservatively.
Regarding the adrenocortical lesions, DNA analysis for
allelic loss at the MEN1 locus shown no loss of hetero-
zygosity [15,31], probably suggesting that they are not a
direct result of inactivation of the MEN1 gene.
Since the malignant potential of MEN1-related adrenal
neoplasia is of important clinical significance, close bio-
chemical and radiologic follow-up is recommended.
Newly diagnosed adrenal lesions should undergone a
control investigation after 6 months and in case of a
stable lesion, control intervals of 2 years seem to be suf-
ficient [32]. Adrenal lesions smaller than 3 cm are
usually asymptomatic and endocrine-inactive with low
malignant potential [32]. Although general agreement
does not exist, several authors [2,18,22] recommend that
adrenocortical tumours greater than 3 cm in diameter
or growing lesion [32] should be surgically removed
because of their malignant potential. Because both adre-
nal lesions in the presented case were greater than
3 cm, bilateral adrenalectomy was performed.
In the patient we describe, a non functional, fully calci-
fied ectopic pelvic kidney was also detected and surgically
removed. Since ectopic kidneys are more susceptible to
diseases such as nephrolithiasis, hydronephrosis, injury of
aberrant vessels or overlying abdominal viscera and
nerves or malignancy than the normally positioned ones,
a non functional pelvic kidney requires removal [33].
Preoperatively, the patient we describe, had elevated
(7.5-fold) serum CA-125 levels. It is well known the high
false positive rate and the poor sensitivity and specificity
of the CA-125. Although cardiovascular, lung and
chronic liver diseases are the most frequent diagnoses in
patients with increased CA-125, other intra-abdominal
non-malignant non-hepatic diseases can also cause eleva-
tion of the CA-125 [34], as in the present case.
Many proteins that localize to the nucleus contain a
polybasic motif, the Nuclear Localization Signal (NLS),
which is necessary for proper nuclear targeting. Menin
contains two NLSs. Both NLS-1 (amino acid 479-497)
and NLS-2 (amino acids 588-608) are present in the
C-fourth of menin [35]. Menin binds to JunD transcrip-
tion factor, a member of Activator Protein 1 family.
JunD regulates transcription from certain promoters by
binding to TRE consensus. Menin-JunD interaction
involves the N-terminus (amino acids 1-40) and midre-
gion (amino acids 323-428) of Menin and requires the
N-terminus of JunD (amino acids 8-70). Menin’s tumor
suppressor involves direct binding to JunD and inhibi-
tion of JunD activated transcription [36].
The patient we describe harbors the germline p.E45V
mutation of the MEN1 gene which, to the best of our
knowledge, has not been previously described in the lit-
erature data. It is a point mutation in exon 2 of MEN1
gene, in nucleotide 134 substituting Adenosine to
Thymine, changing the Glutamic acid (GAG) to Valine
(GTC) in the menin molecule. Although, pathogenetic
mutations of glutamic acid either to lysine (p.E45K) or
glykine (p.E45G) or alanine (p.E45A), have been pre-
viously described [37], the close proximity of this amino
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acid (amino acid 45) to the area (amino acids 1-40) of
menin molecule responsive for Menin-JunD interaction,
poses a possible explanation of the present tumorgenesis
by disrupting Menin-JunD interaction, finally affecting
the tumor suppression function.
In conclusion, we present a MEN1 patient with the
novel p.E45V mutation in the exon 2 of the MEN1
gene, in whom bilateral ACC was detected. Whether
this novel mutation predisposed to bilateral ACC devel-
opment or whether bilateral ACC can also occur in
MEN1 patients, remains to be proved.
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